<DOC>
	<DOCNO>NCT01537757</DOCNO>
	<brief_summary>This study assess pharmacokinetics MK-8931 , ß-secretase inhibitor , participant renal insufficiency . In Part 1 study , pharmacokinetics MK-8931 participant severe renal disease healthy match control participant study . If data Part 1 confirms severe renal impairment alter pharmacokinetics MK-8931 extent require dosage adjustment , study require Part 2 optional . If data support conclusion , Part 2 conduct study pharmacokinetics MK-8931 participant moderate mild renal impairment compare healthy match control .</brief_summary>
	<brief_title>A Two-Part , Single-Dose Study Pharmacokinetics MK-8931 Subjects With Renal Insufficiency ( MK-8931-009 P08535 )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Body Mass Index ≤39 kg/m^2 No clinically significant abnormality electrocardiogram Female participant must postmenopausal surgically sterilize Nonvasectomized men must agree use condom spermicide abstain sexual intercourse , trial 3 month stop medication Inclusion Criteria Specific Renally Impaired Participants : Clinical diagnosis renal insufficiency base Estimated Glomerular Filtration rate ( eGFR ) : severely decrease eGFR , define &lt; 30 mL/min/1.73m^2 participant dialysis ; moderately decrease eGFR , define ≥30 &lt; 60 mL/min/1.73m^2 ; mildly decrease eGFR , define ≥60 &lt; 80 mL/min/1.73m^2 Stable baseline health base medical history , physical examination , vital sign , laboratory test Inclusion Criterion Specific Healthy Participants : eGFR ≥80 mL/min/1.73m^2 Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug , include history presence inflammatory bowel disease , gastrointestinal rectal bleeding ; presence active ulcer ; history major gastrointestinal tract surgery gastrectomy , gastroenterostomy , bowel resection ; history pancreatic injury pancreatitis ; history presence liver disease liver injury ; history urinary obstruction difficulty void History infectious disease within 4 week prior drug administration Positive hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) human immunodeficiency virus ( HIV ) History risk factor Torsades de Pointes ( e.g. , heart failure/cardiomyopathy family history Long QT Syndrome ) Participant kidney remove functioning renal transplant History alcohol drug abuse past 2 year Blood donation loss significant volume blood past 60 day prior dose Previously receive MK8931 History significant multiple and/or severe allergy ( include latex allergy ) , anaphylactic reaction significant intolerability prescription nonprescription drug food History malignancy occur within 5 year immediately screen , except participant adequately treat basal cell squamous cell skin cancer ; situ cervical cancer ; localize prostate carcinoma ; undergone potentially curative therapy evidence recurrence ≥1 year posttherapy Exclusion Criteria Specific Renally Impaired Participants : Rapidly fluctuate renal function determine historical measurement Suspected renal artery stenosis</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>